Karamvir Yadav, Medical Oncologist in Jaipur, India, shared posts on X:
“Can we safely STOP immunotherapy early in MSI mCRC?
New real-world data says YES — if patients respond. No OS/PFS compromise ctDNA-negative → very low relapse risk (~7%) Fixed 2-year duration?
Probably arbitrary Time for response-adapted ICI duration?”
Title: Impact of treatment discontinuation among patients with microsatellite instability or mismatch repair-deficient metastatic colorectal cancer treated with immune checkpoint inhibitors
Authors: J. Ros, M.C. de Grandis, V. Navarro, I. Baraibar, F. Salva, C. Vaghi, A. Garcia, A. Alcaraz, A.M. López, M. Rodriguez, C. Salvà, N. Mulet-Margalef, J.L. Manzano, R. Querol, M. Pampols, E. Castillo, A. Vivancos, J. Tabernero, E. Elez
Read the full article.
Other articles featuring Karamvir Yadav on OncoDaily.